Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Epithelial Ovarian Cancer Market: By Treatment Type Trends, Size, and Future Outlook
- Treatment Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Treatment Type Definitions, Technology Landscape
- Treatment Type Market Drivers
- Product Launches
- Technology Launches
- Treatment Type Market Restraints
Chapter 4. Epithelial Ovarian Cancer Market: By Cancer Type Trends, Size, and Future Outlook
- Cancer Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Cancer Type Definitions, Technology Landscape
- Cancer Type Market Drivers
- Product Launches
- Technology Launches
- Cancer Type Market Restraints
Chapter 5. Epithelial Ovarian Cancer Market: By Distribution Channel Trends, Size, and Future Outlook
- Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Distribution Channel Definitions, Technology Landscape
- Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- Distribution Channel Market Restraints
Chapter 6. Epithelial Ovarian Cancer Market: By End-User Trends, Size, and Future Outlook
- End-User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- End-User Definitions, Technology Landscape
- End-User Market Drivers
- Product Launches
- Technology Launches
- End-User Market Restraints
Chapter 7. Epithelial Ovarian Cancer Market: By Stage Trends, Size, and Future Outlook
- Stage Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Stage Definitions, Technology Landscape
- Stage Market Drivers
- Product Launches
- Technology Launches
- Stage Market Restraints
Chapter 8. Epithelial Ovarian Cancer Market: By Molecule Type Trends, Size, and Future Outlook
- Molecule Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Molecule Type Definitions, Technology Landscape
- Molecule Type Market Drivers
- Product Launches
- Technology Launches
- Molecule Type Market Restraints
Chapter 9. Epithelial Ovarian Cancer Market: By Route of Administration Trends, Size, and Future Outlook
- Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Route of Administration Definitions, Technology Landscape
- Route of Administration Market Drivers
- Product Launches
- Technology Launches
- Route of Administration Market Restraints
Chapter 10. Epithelial Ovarian Cancer Market: Regional Market Trends, Size, and Future Outlook
- North America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
Chapter 11. Epithelial Ovarian Cancer Market: Competitive Landscape
- AstraZeneca
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Roche
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Clovis Oncology
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Tesaro (acquired by GlaxoSmithKline)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Genentech (subsidiary of Roche)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amgen
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eli Lilly and Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Immunogen
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eisai Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Boehringer Ingelheim
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Regeneron Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AbbVie
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Myriad Genetics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Nektar Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Epithelial Ovarian Cancer industry is USD 1.8 billion.
The key factors contributing to the growth of the Epithelial Ovarian Cancer Market are: increasing incidence of ovarian cancer, rising geriatric population, advances in diagnostic techniques, favorable government initiatives, adoption of targeted therapies, development of biosimilars/biobetters, personalized medicine and biomarker-based therapies, and increasing clinical trials.
The key factors hampering the growth of the Epithelial Ovarian Cancer Market include high treatment costs, side effects of therapies, stringent regulatory approvals, and lack of effective screening methods.
The leading component segment in the Epithelial Ovarian Cancer Market is the targeted therapy segment, which includes PARP inhibitors and other targeted therapies for personalized treatment.
The major players operating in the Epithelial Ovarian Cancer Market include AstraZeneca, GlaxoSmithKline, Roche, Merck & Co., Pfizer, Johnson & Johnson, Novartis, Clovis Oncology, Tesaro, Genentech, Amgen, Eli Lilly, Bristol-Myers Squibb, Immunogen, and Eisai Co.
Epithelial Ovarian Cancer Market is Expected to Achieve US$ 3.9 Bn by 2031, registering a CAGR of 10.2% during the forecast period.
The key drivers of the Epithelial Ovarian Cancer Market include increasing incidence of ovarian cancer, rising geriatric population, advances in diagnostic techniques, favorable government initiatives, adoption of targeted therapies, and development of personalized medicine approaches.